专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120315336A1 INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS 审中-公开
标题翻译：可注射的纳米制剂奥兰治泊配方
公开(公告)号：US20120315336A1
公开(公告)日：2012-12-13
申请号：US13463564
申请日：2012-05-03
申请人： Stephen B. Ruddy , David Czekai , Gary Liversidge , Scott A. Jenkins , Elaine M. Liversidge
发明人： Stephen B. Ruddy , David Czekai , Gary Liversidge , Scott A. Jenkins , Elaine M. Liversidge
IPC分类号： A61K9/14 , A61P25/18 , A61P25/08 , A61P25/00 , A61P25/34 , A61P25/24 , A61K31/5513 , A61P25/22 , B82Y5/00
CPC分类号： A61K31/551 , A61K9/0019 , A61K9/10 , A61K9/146 , A61K9/148 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.
摘要翻译：描述了在给药时产生延长的作用时间的颗粒状奥氮平的可注射制剂，以及制备和使用这些制剂的方法。可注射制剂包含颗粒状奥氮平。

2. 发明申请

US20090155331A1 INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS 审中-公开
标题翻译：可注射的纳米制剂奥兰治泊配方
公开(公告)号：US20090155331A1
公开(公告)日：2009-06-18
申请号：US12333233
申请日：2008-12-11
申请人： Stephen B. Ruddy , David Czekai , Gary Liversidge , Scott A. Jenkins , Elaine M. Liversidge
发明人： Stephen B. Ruddy , David Czekai , Gary Liversidge , Scott A. Jenkins , Elaine M. Liversidge
IPC分类号： A61K9/14 , A61K31/551 , A61P25/00
CPC分类号： A61K31/551 , A61K9/0019 , A61K9/10 , A61K9/146 , A61K9/148 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.
摘要翻译：描述了在给药时产生延长的作用时间的颗粒状奥氮平的可注射制剂，以及制备和使用这些制剂的方法。可注射制剂包含颗粒状奥氮平。

3. 发明申请

US20110008435A1 Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds 审中-公开
标题翻译：包含芳基杂环化合物的纳米微粒和控制释放组合物
公开(公告)号：US20110008435A1
公开(公告)日：2011-01-13
申请号：US11672263
申请日：2007-02-07
申请人： John G. Devane , Paul Stark , Niall M.M. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Niall M.M. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/14 , A61K31/496 , A61P25/18
CPC分类号： A61K9/5084
摘要： The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.
摘要翻译：本发明提供一种包含齐拉西酮的组合物，其可用于治疗和预防精神分裂症和类似的精神障碍。在一个实施方案中，组合物包含包含齐拉西酮和至少一种表面稳定剂的纳米颗粒颗粒。纳米颗粒具有小于约2000nm的有效平均粒度。在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送齐拉西酮。本发明还涉及含有这些组合物的剂型，以及治疗和预防精神分裂症和类似精神障碍的方法。

4. 发明申请

US20080124389A1 Nanoparticulate and Controlled Release Compositions Comprising Cyclosporine 失效
标题翻译：包含环孢菌素的纳米颗粒和对照释放组合物
公开(公告)号：US20080124389A1
公开(公告)日：2008-05-29
申请号：US11568692
申请日：2006-04-12
申请人： Scott A. Jenkins , Gary Liversidge
发明人： Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/50 , A61K31/395 , A61K9/14
CPC分类号： A61K9/5084 , A61K9/14 , A61K9/1676 , A61K9/5078 , A61K31/395
摘要： The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米颗粒环孢霉素的组合物。组合物的纳米颗粒环孢菌素颗粒具有直径小于约2000nm的有效平均粒度，并且可用于预防和治疗器官移植排斥和自身免疫性疾病如牛皮癣，类风湿性关节炎和其它相关疾病。本发明还涉及包含环孢菌素或纳米颗粒环孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物以预防和治疗器官移植排斥和自身免疫性疾病如牛皮癣，类风湿性关节炎和其它相关的疾病

5. 发明申请

US20080118556A1 Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone 审中-公开
标题翻译：包含卡比多巴，左旋多巴和恩他卡朋组合的组合物的改良释放
公开(公告)号：US20080118556A1
公开(公告)日：2008-05-22
申请号：US11422226
申请日：2006-06-05
申请人： John G. Devane , Paul Stark , Niall M. M. Fanning , Gurvinder Singh Rekhi , Gary Liversidge , Scott A. Jenkins
发明人： John G. Devane , Paul Stark , Niall M. M. Fanning , Gurvinder Singh Rekhi , Gary Liversidge , Scott A. Jenkins
IPC分类号： A61K31/195 , A61K9/14 , A61K9/20 , A61K9/48 , A61P25/16
CPC分类号： A61K31/195 , A61K9/1676 , A61K9/5078 , A61K9/5084 , A61K31/275 , A61K2300/00
摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers a combination of carbidopa, levodopa and entacapone in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment of Parkinson's disease.
摘要翻译：本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送卡比多巴，左旋多巴和恩他卡朋的组合。多微粒改性释放组合物包含第一组分和至少一个后续组分，第一组分包含含有颗粒的第一组活性成分和至少一种随后的组分，其包含第二组含有颗粒的活性成分。本发明还涉及含有这种多微粒释放组合物的固体口服剂型，以及治疗帕金森病的方法。

6. 发明申请

US20080102121A1 COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE 审中-公开
标题翻译：包含纳米颗粒糊精和受控释放氢化物的组合物
公开(公告)号：US20080102121A1
公开(公告)日：2008-05-01
申请号：US11768169
申请日：2007-06-25
申请人： John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/14 , A61K31/485 , A61K9/00 , A61K31/54 , A61P25/00
CPC分类号： A61K31/485 , A61K9/145 , A61K9/146 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/1676 , A61K9/5078 , A61K9/5084 , A61K31/54
摘要： The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.
摘要翻译：本发明涉及一种组合物，其包含与多颗粒改性释放氢可酮组合物组合的纳米微粒美洛昔康组合物，其在给予患者时以双峰或多峰方式递送氢可酮。多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含第一群含氢可酮的颗粒，所述至少一个随后的组分包含第二组含有氢可酮的颗粒，其中所述组分的组合表现出双峰或多峰释放曲线。本发明还涉及包含这种组合组合物的固体口服剂型。

7. 发明申请

US20100247636A1 Nanoparticulate and controlled release compositions comprising nilvadipine 审中-公开
标题翻译：包含尼伐地平的纳米颗粒和控释组合物
公开(公告)号：US20100247636A1
公开(公告)日：2010-09-30
申请号：US11479013
申请日：2006-06-30
申请人： John G. Devane , Paul Stark , Niall M.M. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Niall M.M. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/48 , A61K31/4422 , A61K9/14 , A61K9/50 , A61K9/26 , A61K9/22 , A61P9/12 , A61P9/00
CPC分类号： A61K9/5026 , A61K9/5047 , A61K9/5084 , A61K31/192 , A61K31/485
摘要： The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders.
摘要翻译：本发明提供一种组合物，其包含可用于治疗和预防高血压或相关心血管疾病的尼伐地平或其盐，衍生物，前药或多晶型物。在一个实施方案中，组合物包含包含尼伐地平或其盐，衍生物，前药或多晶型物和至少一种表面稳定剂的纳米颗粒颗粒。纳米颗粒具有小于约2000nm的有效平均粒度。在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送尼伐地平或其盐，衍生物，前药或多晶型物。本发明还涉及含有这种组合物的剂型，以及治疗和预防高血压或相关心血管疾病的方法。

8. 发明申请

US20080317843A1 NANOPARTICULATE FORMULATIONS OF MODAFINIL 审中-公开
标题翻译： MODAFINIL的纳米制剂配方
公开(公告)号：US20080317843A1
公开(公告)日：2008-12-25
申请号：US11776770
申请日：2007-07-12
申请人： Scott A. Jenkins , Gary Liversidge , David Manser
发明人： Scott A. Jenkins , Gary Liversidge , David Manser
IPC分类号： A61K9/48 , A61K31/165 , A61K9/14 , A61P25/00 , A61K9/00
CPC分类号： A61K9/145 , A61K9/146
摘要： The present invention is directed to compositions comprising a nanoparticulate modafinil compositions, or a salt(s), or an enantiomer(s), or a prodrug(s), or a polymorph(s) or derivative thereof, having improved bioavailability. The nanoparticulate modafinil composition formulation particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of dyssomnias, including but not limited to, narcolepsy, chronic fatigue, eating disorders, compulsive behaviors, ADHD, addictions, substance abuse, sleepiness, nervous system diseases, conditions, syndromes, and symptoms and related diseases, conditions, and symptoms.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米微粒莫达非尼组合物或其一种或多种或多种或多种或多种或多种或多种或多种形式的衍生物的组合物。组合物的纳米微粒莫达非尼组合物制剂颗粒具有小于约2000nm的有效平均粒度，并且可用于治疗睡眠障碍，包括但不限于发作性睡病，慢性疲劳，进食障碍，强迫行为，ADHD，成瘾，药物滥用，嗜睡，神经系统疾病，病症，综合征，症状及相关疾病，病症和症状。

9. 发明申请

US20080279929A1 Nanoparticulate and Controlled Release Compositions Comprising Cefditoren 有权
标题翻译：包含头孢托仑的纳米颗粒和对照释放组合物
公开(公告)号：US20080279929A1
公开(公告)日：2008-11-13
申请号：US11671276
申请日：2007-02-05
申请人： John G. Devane , Paul Stark , Nial M. N. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Nial M. N. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/52 , A61K31/546 , A61K9/14 , A61K9/20 , A61K9/48 , A61P31/00 , A61K9/00
CPC分类号： A61K9/5084
摘要： The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.
摘要翻译：本发明提供一种组合物，其包含可用于治疗和预防感染和相关病症的头孢托仑或其盐，衍生物，前药或其他形式，例如匹戊头孢托仑。本发明提供一种组合物，其包含包含头孢托仑或其盐，衍生物，前药或其它形式的纳米颗粒颗粒和至少一种表面稳定剂。纳米颗粒具有小于约2000nm的有效平均粒度。本发明还提供以脉动或连续方式递送头孢托仑或其盐衍生物，前药或其它形式或包含其的纳米颗粒的组合物。

10. 发明申请

US20080254114A1 Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles 审中-公开
标题翻译：包含杂环酰胺衍生物纳米颗粒的控制释放组合物
公开(公告)号：US20080254114A1
公开(公告)日：2008-10-16
申请号：US11571377
申请日：2006-03-02
申请人： Scott A. Jenkins , Gary Liversidge
发明人： Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/16 , A61K31/404 , A61K9/54 , A61K9/26 , A61P11/06
CPC分类号： A61K9/145 , A61K9/146 , A61K9/2018 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K9/2077
摘要： The present invention is directed to compositions comprising nanoparticulate heterocyclic amide derivative and preferably zafirlukast nanoparticles, also collectively referred to as “active ingredient,” having improved solubility in water. The nanoparticles of the composition have an effective average particle size of less than about 2,000 nm, and are useful in the treatment of asthma. The invention also relates to a multiparticulate modified release composition comprising the active ingredient that in operation delivers the drug in a pulsed or bimodal manner for the treatment of asthma. The controlled release composition comprises an immediate release component and a modified release component. The immediate release component comprises a first population of heterocyclic amide derivative, and preferably zafirlukast particles, and the modified release component comprises a second population of heterocyclic amide derivative, and preferably zafirlukast nanoparticles, and a controlled release component, wherein the combination of the immediate release and modified release components in operation delivers the active ingredient in a pulsed or bimodal manner. The heterocyclic amide derivative can be released from the multiparticulate particles in an erosable, diffusion or osmotic controlled release system.
摘要翻译：本发明涉及包含纳米颗粒杂环酰胺衍生物和优选扎非司酮纳米颗粒的组合物，其也统称为“活性成分”，其具有改善的在水中的溶解度。组合物的纳米颗粒具有小于约2,000nm的有效平均粒度，并且可用于治疗哮喘。本发明还涉及一种多微粒改性释放组合物，其包含在操作中以脉冲或双峰方式递送药物以治疗哮喘的活性成分。控释组合物包含立即释放组分和改性释放组分。立即释放组分包含第一批杂环酰胺衍生物，优选扎法司他颗粒，并且改性释放组分包含第二组杂环酰胺衍生物，优选扎非司酮纳米颗粒和控释组分，其中立即释放组合并且操作中的改性释放组分以脉冲或双峰方式递送活性成分。杂环酰胺衍生物可以在可侵蚀，扩散或渗透控制释放系统中从多颗粒颗粒中释放。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式